Diagnostic methods for drug screening for Alzheimer's disease

Details Diagnostic methods for drug screening for Alzheimer's disease Diagnostic methods for drug screening for Alzheimer's disease

2005-11-01

2005-11-01

Brumback, Brenda (Department: 1647)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

C435S352000, C435S354000

Reexamination Certificate

active

06960470

ABSTRACT:
Methods of screening candidate drugs for the treatment of Alzheimer's disease are provided. Employing tissue slices of mutant mouse hippocampal cells having an extra copy of a mutant form of the presenilin-1 gene, it is found that these cells have enhanced potentiation to tetanic stimuli. By subjecting both wild-type and mutant hippocampal cells to tetanic stimuli in the presence of a candidate drug, reduction of the enhanced potentiation of the mutant cells without significant change in the potentiation of the wild-type cells indicates a successful candidate.

REFERENCES:
Skolnick et al., Trends in Biotech 18(1):34-39, 2000.
Kandel et al., Principles of Neural Science, Elsevier, 3rd Ed., 1991:206-209 and 1019-23.
Crooke et al., Nature Medicine Apr. 1998 4(4):452-5.
Voet & Voet (1995) “Biochemistry (2nd Ed.): Chapter 15 Introduction to Metabolism” (pp. 412-442).
Allsop et al. “Modulation of b-amyloid production and fibrillization.” Biochem. Soc. Symp. 67: 1-14.
Lodash et al. (1997) “Molecular Cell Biology: Chapter 8 ‘Genetic Analysis in Cell Biology’” (pp. 263-303).
Bradford (1986) “Chemical Neurobiology An Introduction to Neurochemistry Two Inhibitory Amino Acids: GABA and Glycine.” (pp. 229-242).
Ikeda et al. (Dec. 1996) “The Clinical Phenotype of Two Missense Mutations in the Presenilin I Gene in Japanese Patients.” Ann. Neurol. 40(6): 912-917.
Skolnick & Fetrow (2000) “From genes to protein structure and function: novel applications of computational approaches in the genomic era.” Trends in Biotech. 18(1): 34-39.
Jobling & Holmes (1991) “Analysis of structure and function of the B Subunit of cholera toxin by the use of site-directed mutagenesis.” Molecular Microbiology 5(7): 1755-67.
Hevers & Luddens (Aug. 1998) “The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes.” Mol. Neurobiol. 18(1): 35-86.
Smith, Elements of Molec. Neurobiol., 2nd Ed., 74-82 and 460-70, 1996.
Parent et al., Neurobiology of Disease 6:56-62, Jun. 17, 1999.
Bliss et al. (1993)Nature361:31-39.
Borchelt et al. (1996)Neuron17: 1005-1013.
Evans, et al. (1996)Neuropharmacology35: 347-357.
Fastbom et al. (1998)Alzheimer Dis Assoc. Disord.12: 14-17.
Guo et al. (1996)Neuroreport. 8: 379-383.
Muir et al. (1996)J. Cereb. Blood Flow Metab. (16): 1211-1218.
Ohkuma et al. (1994)Jpn. J. Pharmacol64:125-128.
Shen, et al. (1997)Cell89: 629-639.
Wigstrom et al. (1986)J. Physiol.(Paris) 81: 228-236.
Wong et al. (1997)Nature387: 288-292.
Borchelt et al. (1997)Neuron19:939-45.
Darnell et al. (1986)Molec. Cell Biologypp. 400-401.
Davis et al. (1998)Neuron20:603-09.
Lee et al. (1997)Nat. Med.3:756-60.
Naruse et al. (1998)Neuron21:1213-21.
Parent et al. (1999)Neurobiology of Disease6:56-62.
Smith (1996)Elements of Molec. Neurobiology, 2ndEd, pp. 74-82 and 460-470.

Affiliated with

Also associated with

Rating

Diagnostic methods for drug screening for Alzheimer's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Diagnostic methods for drug screening for Alzheimer's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostic methods for drug screening for Alzheimer's disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3493484